Literature DB >> 8794313

Recombinant adeno-associated virus-mediated high-efficiency, transient expression of the murine cationic amino acid transporter (ecotropic retroviral receptor) permits stable transduction of human HeLa cells by ecotropic retroviral vectors.

J Bertran1, J L Miller, Y Yang, A Fenimore-Justman, F Rueda, E F Vanin, A W Nienhuis.   

Abstract

Adeno-associated virus has a broad host range, is nonpathogenic, and integrates into a preferred location on chromosome 19, features that have fostered development of recombinant adeno-associated viruses (rAAV) as gene transfer vectors for therapeutic applications. We have used an rAAV to transfer and express the murine cationic amino acid transporter which functions as the ecotropic retroviral receptor, thereby rendering human cells conditionally susceptible to infection by an ecotropic retroviral vector. The proportion of human HeLa cells expressing the receptor at 60 h varied as a function of the multiplicity of infection (MOI) with the rAAV. Cells expressing the ecotropic receptor were efficiently transduced with an ecotropic retroviral vector encoding a nucleus-localized form of beta-galactosidase. Cells coexpressing the ecotropic receptor and nucleus-localized beta-galactosidase were isolated by fluorescence-activated cell sorting, and cell lines were recovered by cloning at limiting dilution. After growth in culture, all clones contained the retroviral vector genome, but fewer than 10% (3 of 47) contained the rAAV genome and continued to express the ecotropic receptor. The ecotropic receptor coding sequences in the rAAV genome were under the control of a tetracycline-modulated promoter. In the presence of tetracycline, receptor expression was low and the proportion of cells transduced by the ecotropic retroviral vector was decreased. Modulation of receptor expression was achieved with both an episomal and an integrated form of the rAAV genome. These data establish that functional gene expression from an rAAV genome can occur transiently without genome integration.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8794313      PMCID: PMC190719     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

1.  Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy.

Authors:  Y Yang; F A Nunes; K Berencsi; E E Furth; E Gönczöl; J M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

2.  Use of retroviral vectors for gene transfer and expression.

Authors:  A D Miller; D G Miller; J V Garcia; C M Lynch
Journal:  Methods Enzymol       Date:  1993       Impact factor: 1.600

3.  High-efficiency transfer of the T cell co-stimulatory molecule B7-2 to lymphoid cells using high-titer recombinant adeno-associated virus vectors.

Authors:  J A Chiorini; C M Wendtner; E Urcelay; B Safer; M Hallek; R M Kotin
Journal:  Hum Gene Ther       Date:  1995-12       Impact factor: 5.695

Review 4.  The basic science of gene therapy.

Authors:  R C Mulligan
Journal:  Science       Date:  1993-05-14       Impact factor: 47.728

5.  Envelope-binding domain in the cationic amino acid transporter determines the host range of ecotropic murine retroviruses.

Authors:  L M Albritton; J W Kim; L Tseng; J M Cunningham
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

6.  Inducible, high-level production of infectious murine leukemia retroviral vector particles pseudotyped with vesicular stomatitis virus G envelope protein.

Authors:  Y Yang; E F Vanin; M A Whitt; M Fornerod; R Zwart; R D Schneiderman; G Grosveld; A W Nienhuis
Journal:  Hum Gene Ther       Date:  1995-09       Impact factor: 5.695

7.  Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector.

Authors:  T R Flotte; S A Afione; C Conrad; S A McGrath; R Solow; H Oka; P L Zeitlin; W B Guggino; B J Carter
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-15       Impact factor: 11.205

8.  Retroviral infection and expression of cationic amino acid transporters in rodent hepatocytes.

Authors:  E I Closs; I H Borel Rinkes; A Bader; M L Yarmush; J M Cunningham
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

9.  A gene transfer strategy for making bone marrow cells resistant to trimetrexate.

Authors:  H T Spencer; S E Sleep; J E Rehg; R L Blakley; B P Sorrentino
Journal:  Blood       Date:  1996-03-15       Impact factor: 22.113

10.  Adeno-associated virus 2-mediated high efficiency gene transfer into immature and mature subsets of hematopoietic progenitor cells in human umbilical cord blood.

Authors:  S Z Zhou; S Cooper; L Y Kang; L Ruggieri; S Heimfeld; A Srivastava; H E Broxmeyer
Journal:  J Exp Med       Date:  1994-06-01       Impact factor: 14.307

View more
  17 in total

Review 1.  Adeno-associated virus vectors and hematology.

Authors:  D W Russell; M A Kay
Journal:  Blood       Date:  1999-08-01       Impact factor: 22.113

2.  Genetic fate of recombinant adeno-associated virus vector genomes in muscle.

Authors:  Bruce C Schnepp; K Reed Clark; Dori L Klemanski; Christina A Pacak; Philip R Johnson
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

3.  Long-term engraftment and angiogenic properties of lentivirally transduced adipose tissue-derived stromal cells.

Authors:  Rosalinda Madonna; Roberto Bolli; Gregg Rokosh; Raffaele De Caterina
Journal:  Mol Biotechnol       Date:  2013-05       Impact factor: 2.695

4.  Transduction of human primitive repopulating hematopoietic cells with lentiviral vectors pseudotyped with various envelope proteins.

Authors:  Yoon-Sang Kim; Matthew M Wielgosz; Phillip Hargrove; Steven Kepes; John Gray; Derek A Persons; Arthur W Nienhuis
Journal:  Mol Ther       Date:  2010-04-06       Impact factor: 11.454

5.  Adeno-associated virus vector integration junctions.

Authors:  E A Rutledge; D W Russell
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

6.  Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques.

Authors:  Philip R Johnson; Bruce C Schnepp; Mary J Connell; Daniela Rohne; Suzanne Robinson; Georgia R Krivulka; Carol I Lord; Rebekah Zinn; David C Montefiori; Norman L Letvin; K Reed Clark
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

7.  Recombinant adeno-associated virus mediates a high level of gene transfer but less efficient integration in the K562 human hematopoietic cell line.

Authors:  P Malik; S A McQuiston; X J Yu; K A Pepper; W J Krall; G M Podsakoff; G J Kurtzman; D B Kohn
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

8.  Development of high-titer retroviral producer cell lines by using Cre-mediated recombination.

Authors:  E F Vanin; L Cerruti; N Tran; G Grosveld; J M Cunningham; S M Jane
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

9.  Design and packaging of adeno-associated virus gene targeting vectors.

Authors:  R K Hirata; D W Russell
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

10.  Adeno-associated virus type 2-mediated transfer of ecotropic retrovirus receptor cDNA allows ecotropic retroviral transduction of established and primary human cells.

Authors:  K Qing; T Bachelot; P Mukherjee; X S Wang; L Peng; M C Yoder; P Leboulch; A Srivastava
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.